BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05844423 (VAX24 in invasive pneumococcal disease prevention): BVCT ex-ante prediction vs. reported outcome

On 12 May 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 31 Mar 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (non-inferior-and-non-superior).

Clinical Trial

NCTID
NCT05844423
Drug Name
VAX24
Drug MoA
24-valent pneumococcal conjugate antigen-based vaccine
Drug Modality
Vaccine
Drug Class
First-In-Class
Therapeutic Area
Infections
Indication
invasive pneumococcal disease prevention
Human Patients
802
Sponsor
Vaxcyte
Phase
Phase 2

Prediction of , index 1599

Prospective Prediction
Prediction Index
1599
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit non-inferior-and-non-superior-to PCV15/PCV20)
Technical Prediction
SUCCESS (statistically significant clinical benefit non-inferior-and-non-superior-to PCV15/PCV20)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
323 days in advance
Readout Data Interpretation
VAX24 mid-dose met the non-inferiority criteria on relative seroconversion rates compared with PCV20
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (non-inferior-and-non-superior)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines
Phase
Phase 2
Status
Completed
Enrollment
802
Lead sponsor
Vaxcyte, Inc.
Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL: 0.5 ml dose of 1.1 mcg VAX-24; BIOLOGICAL: 0.5 ml dose of PCV20; BIOLOGICAL: 0.5 ml dose of 2.2 mcg VAX-24; BIOLOGICAL: 0.5 ml dose of 2.2/4.4 mcg VAX-24
Design
Randomized · Parallel · Quadruple
Primary purpose
Prevention
Start
2023-03-29
Primary completion
2025-08-25
Completion
2025-08-25
Primary outcomes
  • Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccination (7 days after each vaccination)
  • Percentage of participants with any solicited systemic AE within 7 days after each vaccination (7 days after each vaccination)
  • Percentage of participants with any related Serious Adverse Events (SAE) within 6 months after last vaccination (6 months after last vaccination)

NCT05844423 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials